PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolism

Results from ENGULF trial display restoration of heart dimensions and blood flow from use of catheter-based device

Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolism
2024-05-03
(Press-News.org) Long Beach, Calif. – May 3, 2024 – Late-breaking data from the ENGULF trial showed that a novel dual-action thrombectomy device was effective and safe in treating acute pulmonary embolism (PE). The safety and effectiveness results were presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and simultaneously published in JSCAI.

 

PE is a serious cardiovascular event where a blood clot causes issues with blood flow and oxygen levels in the lungs. It can be life-threatening, with up to 30% of individuals dying within one month of diagnosis. Despite recent advances in therapeutic options, PE still carries a high risk of mortality and morbidity with few FDA-cleared thrombectomy catheters available to physicians.

 

The ENGULF trial is a prospective, single-arm, first-in-human, safety and feasibility study evaluating a novel embolectomy catheter system for the treatment of acute PE with a steerable and expandable funnel and an internal agitator, the Hēlo™ PE Thrombectomy System. Patients underwent a pre- and 48-hour post-procedural computed tomography (CT) scan. The primary efficacy outcome was the percent difference in the pre-to-post procedural right ventricle–to–left ventricle (RV/LV) ratios. The primary and secondary safety outcomes were all-cause mortality, major life-threatening bleeding, device-related serious adverse events, pulmonary or cardiac injury, and clinical decompensation at 48 hours and 30 days post-procedure.

 

All 25 patients from eight centers underwent successful embolectomy. The mean RV/LV ratio was 1.53±0.27 at baseline and 1.15±0.18 at 48 hours post-procedure (23.2%±12.81% change). Of note, there were no major adverse events at 48 hours and no deaths at 30 days.

 

“Although more rigorous studies are needed, RV/LV ratio is the most important predictor of dysfunction and adverse outcomes in acute PE, and it is exciting to see that the RV/LV ratio reduction was just as much as other FDA-approved devices on the market without any large safety concerns in a new first-in-human device,” said Tai Kobayashi, MD, Assistant Professor of Clinical Medicine at Penn Medicine, and lead author of the study. “This technology represents the marriage between large and small-bore embolectomy, which allows for operators to travel through the heart with a smaller catheter but expand a larger funnel that matches the size of the large bore catheters – leaving a smaller footprint and lowering the risk of hemodynamic impact for the patient.”  

 

“For the field of interventional PE therapies to fully reach its promise, continued innovation is needed to optimize our procedural workflows across the wide array of patients affected by this disease,” said Jay Giri MD, MPH, Director of the Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania, senior author of the study, and national principal investigator of the study. “The ENGULF trial is an important step in this process, demonstrating that a novel, purpose-built PE thrombectomy catheter can achieve excellent results even among its earliest users.”

 

Session Details:

“First in Human Safety and Feasibility of a Novel Catheter Thrombectomy Device for the Treatment of Pulmonary Embolism (The ENGULF Trial)” Friday, May 3, 2024; 2:26-2:33 PM PT Long Beach Convention Center, 104A, First Level  

###

 

About Society for Cardiovascular Angiography & Interventions (SCAI)

 

The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 4,500 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease. For more information, visit https://scai.org/. 

 

For more information about the SCAI 2024 Scientific Sessions, visit https://scai.org/scai-2024-scientific-sessions. Follow @SCAI on X (formerly Twitter) and on LinkedIn for the latest heart health news and use #SCAI2024 to follow the latest discussions.

 

END


[Attachments] See images for this press release:
Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolism

ELSE PRESS RELEASES FROM THIS DATE:

Biomimetic transcatheter aortic heart valve offers new option for aortic stenosis patients

Biomimetic transcatheter aortic heart valve offers new option for aortic stenosis patients
2024-05-03
Long Beach, Calif. – May 3, 2024 – Recent findings from a study on a transcatheter heart valve (THV) system, which includes a new class of transcatheter aortic valve, showed positive results in the device's ability to function as a healthy and natural aortic valve in patients with aortic stenosis (AS). The late-breaking data will be presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.   AS is a thickening and narrowing of the aortic valve that can reduce blood flow to ...

SMART trial reaffirms hemodynamic superiority of TAVR self-expanding valve in aortic stenosis patients with a small annulus over time and regardless of age

SMART trial reaffirms hemodynamic superiority of TAVR self-expanding valve in aortic stenosis patients with a small annulus over time and regardless of age
2024-05-03
Long Beach, Calif. – May 3, 2024 – Additional analysis from the SMall Annuli Randomized To Evolut or SAPIEN (SMART) study demonstrated clinical non-inferiority of self-expanding valves (SEV) versus balloon-expandable valves (BEV) in aortic stenosis patients undergoing transcatheter aortic valve replacement (TAVR) and confirmed valve performance superiority over time based on hemodynamics. Data also showed similar positive results in two age groups (< or ≥ 80 years old). The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions ...

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
2024-05-03
Study Title: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore) Publication: American Urological Association Annual Meeting Plenary, May 3, 2024 Dana-Farber Cancer Institute author: Xiao X. Wei, MD Summary: In a follow-on analysis of results from the phase 3 PSMAfore study, clinical investigators from Dana-Farber and elsewhere found that clinical outcomes consistently favored 177Lu-PSMA-617 over a change from one androgen receptor pathway inhibitor (ARPI) to another, regardless of which ARPI patients received first. ...

Studies highlight need for tailored treatment options for women with peripheral artery disease

Studies highlight need for tailored treatment options for women with peripheral artery disease
2024-05-03
Late-Breaking Data Shows Endovascular Therapy Results in One-Third Reduction in Post-Procedural Complications for Women with PAD   Women and Asian Americans Less Likely to Undergo Endovascular Revascularization for PAD Compared to Men and Other Races    Long Beach, Calif. – May 3, 2024 – New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and revascularization. The data ...

Women and Black patients less likely to receive catheter-based treatment for pulmonary embolism

Women and Black patients less likely to receive catheter-based treatment for pulmonary embolism
2024-05-03
Long Beach, Calif. – May 3, 2024 – New data from the REAL-PE analysis investigated catheter-based pulmonary embolism (PE) treatment, showing women and Black people were less frequently treated with minimally invasive therapy compared to men or non-Black patients. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.                                                                                                              ...

Pilot program improves well-being of families during advanced care planning

2024-05-03
WASHINGTON (May 3, 2024) – Children with life-limiting rare diseases and their caregivers face tremendous stress and anxiety about the heart-breaking decisions before them. A new intervention – designed at Children’s National Hospital to support the palliative needs of these families – improved their spiritual and emotional well-being, according to new research published in the journal, Pediatrics.    Called FACE Rare (FAmily CEntered Pediatric Advance Care Planning Intervention for Rare Diseases), the counseling tools were found to be safe, effective and increased feelings of peace among families in this underserved ...

The key role of Galectin-3 in brain tumour development

2024-05-03
A research group at the Department of Biochemistry and Molecular Biology of the University of Seville has made a significant advance by discovering the crucial role of the protein Galectin-3 in the progression of various types of brain tumours. In these tumours, the most abundant immune system cells, microglia and macrophages, overexpress Galectin-3, which creates an immunosuppressed environment which inhibits the action of other immune cells against cancer cells. In vitro findings have shown that specific inhibition of Galectin-3 in microglial cells promotes expression of proinflammatory markers and reverses the presence of key immunosuppressive ...

Announcing Junevity as Tier 3 Sponsor of ARDD 2024

Announcing Junevity as Tier 3 Sponsor of ARDD 2024
2024-05-03
The University of Copenhagen is excited to announce Junevity as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online. Junevity is rewinding diseases of aging with novel transcription factor medicines. Based on 6 years of breakthrough research at UCSF, Junevity's REWINDTM platform identifies new targets based on large-scale genomics, machine learning, and cell aging experiments. Junevity is advancing multiple therapeutic programs towards ...

Climate change amplifies severity of combined wind-rain extremes over the UK and Ireland

2024-05-03
Climate change will cause an increase in extreme winter storms combining strong winds and heavy rainfall over the UK and Ireland, new research has shown. The new study was led by experts at Newcastle University and the Met Office and investigated how future climate change may influence compound wind-rain extremes, which are events where extreme wind and rainfall occur simultaneously. The researchers analysed data from climate simulations covering control (1981-2000) and future (2060-2081) periods, ...

Exeter announces new £3.4 million global funding for solutions to antifungal drug resistance

Exeter announces new £3.4 million global funding for solutions to antifungal drug resistance
2024-05-03
Researchers working on solutions for antifungal resistance are being encouraged to apply to a new £3.4 million fund led by the University of Exeter with UK government funding. The new fund, called FAILSAFE (Fungal AMR Innovations for LMICS: Solutions and Access For Everyone), is being launched by the University of Exeter’s MRC Centre for Medical Mycology, in partnership with the UK Department of Health and Social Care’s Global AMR Innovation Fund (GAMRIF). Life-threatening fungal diseases take as many lives annually as TB or malaria, but the organisms ...

LAST 30 PRESS RELEASES:

From camera to lab: Dr. Etienne Sibille transforms brain aging and depression research

Depression rates in LGBTQIA+ students are three times higher than their peers, new research suggests

Most parents don’t ask about firearms in the homes their kids visit

Beer-only drinkers’ diets are worse than wine drinkers

Eco-friendly biomass pretreatment method yields efficient biofuels and adsorbents

How graph convolutions amplify popularity bias for recommendation?

New lignin-based hydrogel breakthrough for wound healing and controlled drug release

Enhancing compatibility and biodegradability of PLA/biomass composites via forest residue torrefaction

Time alone heightens ‘threat alert’ in teenagers – even when connecting on social media

Study challenges long-held theories on how migratory birds navigate 

Unlocking the secrets of ketosis

AI analysis of PET/CT images can predict side effects of immunotherapy in lung cancer

Making an impact. Research studies a new side of helmet safety: faceguard failures

Specific long term condition combinations have major role in NHS ‘winter pressures’

Men often struggle with transition to fatherhood amid lack of targeted information and support

More green space linked to fewer preventable deaths in most deprived areas of UK

Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma

A formula for life? New model calculates chances of intelligent beings in our Universe and beyond

Could a genetic flaw be the key to stopping people craving sugary treats?

Experts urge complex systems approach to assess A.I. risks

Fossil fuel CO2 emissions increase again in 2024

Winners of Applied Microbiology International Horizon Awards 2024 announced

A toolkit for unraveling the links between intimate partner violence, trauma and substance misuse

Can everyday physical activity improve cognitive health in middle age?

Updated guidance reaffirms CPR with breaths essential for cardiac arrest following drowning

Study reveals medical boards rarely discipline physician misinformation

New treatment helps children with rare spinal condition regain ability to walk

'Grow Your Own' teacher prep pipeline at the University of Louisiana at Lafayette funded by US Department of Education

Lab-grown human immune system uncovers weakened response in cancer patients

More than 5 million Americans would be eligible for psychedelic therapy, study finds

[Press-News.org] Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolism
Results from ENGULF trial display restoration of heart dimensions and blood flow from use of catheter-based device